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OBJECTIVE—Imatinib has been reported to induce regression
of type 2 diabetes in chronic leukemia patients. However, the
mechanism of diabetes amelioration by imatinib is unknown, and
it is uncertain whether imatinib has effects on type 2 diabetes
itself without other confounding diseases like leukemia. We
studied the effect of imatinib on diabetes in db/db mice and
investigated possible mechanism’s underlying improved glyce-
mic control by imatinib.
RESEARCH DESIGN AND METHODS—Glucose tolerance
and insulin tolerance tests were done after daily intraperitoneal
injection of 25 mg/kg imatinib into db/db and C57BL/6 mice for 4
weeks. Insulin signaling and endoplasmic reticulum stress re-
sponses were studied by Western blotting. -Cell mass and
apoptotic -cell number were determined by combined terminal
deoxynucleotidyl transferase–mediated dUTP nick-end labeling
(TUNEL) staining and insulin immunohistochemistry. The in
vitro effect of imatinib was studied using HepG2 cells.
RESULTS—Imatinib induced remission of diabetes in db/db
mice and amelioration of insulin resistance. Expression of endo-
plasmic reticulum stress markers in the liver and adipose tissues
of db/db mice, such as phospho-PERK, phospho-eIF2, TRB3,
CHOP, and phospho–c-Jun NH2-terminal kinase, was reduced by
imatinib. Insulin receptor substrate-1 tyrosine phosphorylation
and Akt phosphorylation after insulin administration were im-
proved by imatinib. Serum aminotransferase levels and hepatic
triglyceride contents were decreased by imatinib. Pancreatic
-cell mass was increased by imatinib, accompanied by de-
creased TUNEL
 -cell and increased BrdU
 -cell numbers.
Imatinib attenuated endoplasmic reticulum stress in hepatoma
cells in vitro.
CONCLUSIONS—Imatinib ameliorated endoplasmic reticulum
stress and induced remission of diabetes in db/db mice. Imatinib
or related compounds could be used as therapeutic agents
against type 2 diabetes and metabolic syndrome. Diabetes 58:
329–336, 2009
T
ype 2 diabetes is a metabolic disease that affects
2.8% of all age-groups worldwide, and this pro-
portion is expected to increase to 4.4% by 2030
(1). The two major components of the pathogen-
esis of type 2 diabetes are insulin resistance and -cell
failure. However, the biochemical mechanisms underlying
these two phenomena are incompletely understood.
Regarding the mechanism of insulin resistance, several
hypotheses have been proposed, for example, increased
circulating free fatty acid level, mitochondrial dysfunction,
elevated reactive oxygen species production, and in-
creased levels of proinﬂammatory mediators (2–4). Down-
stream of these molecules or events, disturbance in
intracellular signaling, such as c-Jun NH2-terminal kinase
(JNK) phosphorylation, IKK activation, or endoplasmic
reticulum stress responses, may play a role in the devel-
opment of insulin resistance (5–7).
Imatinib mesylate (Gleevec) is a well-known anticancer
agent that has a dramatic effect on chronic myelogenous
leukemia (CML) and gastrointestinal stromal tumor by
speciﬁcally inhibiting Bcr-Abl or Kit kinase (8,9). Recently,
it was reported that imatinib induced remission of type 2
diabetes in patients having both CML and type 2 diabetes
(10,11). The effect of imatinib on animal models of type 1
diabetes resulting from islet injury has also been studied
(12,13). However, the effect of imatinib on type 2 diabetes
itself in patients or experimental animals without other
confounding diseases has not been explored. Further-
more, the mechanism of the improvement of type 2
diabetes by imatinib is unknown. In fact, the possibility
that improved glucose tolerance in type 2 diabetic patients
with CML by imatinib is due to a positive side effect of
leukemic responses leading to the nonspeciﬁc generalized
improvement of health status cannot be eliminated (11).
Thus, it is uncertain whether imatinib could improve
glycemic control in type 2 diabetic patients or animals
without other confounding diseases. To address this ques-
tion, we investigated whether imatinib could improve
glycemic control in diabetic db/db mice.
RESEARCH DESIGN AND METHODS
Cell line and reagents. HepG2 hepatoma cells (American Type Culture
Collection, Manassas, VA) were cultured in Dulbecco’s modiﬁed Eagle’s
medium–10% fetal bovine serum containing 2 mmol/l glutamine and penicillin-
streptomycin (Gibco, Carlsbad, CA). All other chemicals were obtained from
Sigma (St. Louis, MO), unless stated otherwise.
In vivo models. Imatinib (provided by Dr. R. Halse, Novartis Pharma, Basel,
Switzerland) was dissolved fresh in PBS and injected intraperitoneally into
db/db (The Jackson Laboratory, Bar Harbor, ME) and control C57BL/6 mice.
Control littermate db/db mice were treated with PBS. Intraperitoneal glucose
tolerance test (IPGTT) was carried out after overnight fasting by intraperito-
neal injection of 1 g/kg glucose (14). Blood glucose concentrations were
determined using a One Touch glucometer (Lifescan, Milpitas, CA) before (0
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DIABETES, VOL. 58, FEBRUARY 2009 329min) and 15, 30, 60, and 120 min after glucose injection. Insulin tolerance test
(ITT) was conducted by intraperitoneal injection of 1 unit/kg regular insulin to
fasted mice and measuring blood glucose levels at 0, 15, 30, 60, and 120 min.
Insulinogenic index was calculated according to a published method
(insulin15min/glucose15min) (15,16). Serum insulin concentrations were de-
termined using a commercial mouse insulin ELISA kit (Shibayagi, Gunma,
Japan). Pair feeding was conducted as previously described (17). To examine
insulin signaling in vivo, regular insulin (5 units/kg) was injected into the tail
vein. Five minutes after insulin infusion, the liver and epididymal adipose
tissues were removed and frozen in liquid nitrogen until use. Alanine
aminotransferase/aspartate aminotransferase (ALT/AST) levels were mea-
sured using a Fuji Dri-Chem 3000 blood chemistry analyzer (Fuji Photo,
Tokyo, Japan) according to the manufacturer’s instruction. All animal exper-
iments were conducted in accordance with the institutional guidelines of
Samsung Medical Center Animal Facility.
Western blotting. Western blotting was as previously described (18) using
anti–phospho-JNK Thr183/Tyr185, anti–insulin receptor substrate-1 (anti–IRS-
1), anti–phospho-eukaryotic initiation factor 2a (elF2) Ser51, anti–phospho-
double-stranded RNA-activated protein-like endoplasmic reticulum kinase
(PERK) Thr980, anti-Akt, anti–phospho-Akt Thr308 (Cell Signaling, Beverly,
MA), anti–phospho-IRS-1 Ser307 (Upstate Biotechnology, Lake Placid, NY),
anti–phospho-IRS-1 Tyr612 (Biosource International, Camarillo, CA), anti-
GADD153/C/EBP homologous protein (CHOP) (Sigma), anti-elF2, anti-JNK
(Santa Cruz Biotechnology, Santa Cruz, CA), anti–-actin (Abcam, Cambridge,
MA), and anti-TRB3 (provided Dr. S.H. Koo, Sungkyunkwan University School
of Medicine) antibodies.
Triglyceride measurement. Lipid was extracted from homogenized tissue
using a 2:1 chloroform:methanol mixture. Lipid residue after evaporation was
suspended in 1% Triton X-100 in 100% ethanol and mixed with Free Glycerol
Reagent containing lipase (Sigma). After incubation at 37°C for 5 min, A540
was measured for calculation of triglyceride (TG) concentrations on a
standard curve.
-Cell mass. To measure pancreatic -cell mass, formalin-ﬁxed sections of
the pancreas were deparafﬁnized and brieﬂy microwaved in 0.01 mol/l sodium
citrate buffer (pH 6.0). They were then incubated with an appropriate dilution
of anti-insulin antibody (DAKO, Kyoto, Japan) after goat serum blocking.
Incubation with biotinylated anti–guinea pig IgG antibody and then with
avidin-biotin-peroxidase complex (Vector, Burlingame, CA) followed. Diami-
nobenzidine was used as a color substrate. Point-counting morphometry on
insulin antibody-stained sections was done to calculate the relative -cell area
(19) Terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling
(TUNEL) staining combined with immunohistochemistry was conducted to
identify apoptotic -cells in pancreatic sections as described previously (18).
To quantify apoptotic -cells, 50 islets from more than three parallel
sections obtained at different cut levels were analyzed per mouse by a single
observer, unaware of mouse genotype. To quantify -cell proliferation, 100
g/g 5-bromo-2-deoxyuridine (BrdU) (Serva, Heidelberg, Germany) in 5
mmol/l NaOH-PBS was injected intraperitoneally. Pancreatic sections pre-
pared 12 h after BrdU injection were treated with 4.2 N HCl in PBS and then
stained with anti-BrdU antibody. After immunohistochemistry using anti-
insulin antibody as the primary antibody, numbers of BrdU
 -cells were
calculated as described above. The numbers of TUNEL
 or BrdU
 -cells
were normalized to total islet area measured by a computer-assisted method
using the Axion Vision 4 software (Zeiss, Goettingen, Germany).
Statistical analysis. All values are expressed as means  SE of three
independent experiments performed in triplicate to ensure reproducibility.
Student’s t test was used to compare values between two groups unless stated
otherwise. Wilcoxon’s rank-sum test was used when normal distribution of the
data could not be ascertained. P values 	0.05 were considered to represent
statistically signiﬁcant differences.
RESULTS
Remission of diabetes by imatinib. Initially, we studied
the effect of imatinib on diabetes of db/db mice that
develop classical obesity-induced diabetes. Intraperitoneal
injection of 25 mg/kg imatinib to 5- to 7-week-old diabetic
db/db mice (16.7 mmol/l) daily (six times a week) for 1–4
weeks induced a dramatic reduction in blood glucose
levels. Even after 1 week of treatment at 25 mg/kg, blood
glucose levels, although still in the diabetic range, were
signiﬁcantly lower than those of control db/db mice
treated with PBS (P 	 0.01). The decrease of blood
glucose levels was more prominent 2–4 weeks after ima-
tinib treatment (P 	 0.005), and blood glucose levels at 4
weeks after treatment were not signiﬁcantly different from
those of control C57BL/6 mice (P  0.1) (Fig. 1A). We also
treated db/db mice with imatinib at 50–75 mg/kg daily,
which has been used for treatment of murine models of
cancer (8,20). In this case, blood glucose levels were
normalized since 1 week after commencing treatment,
demonstrating more dramatic effects (data not shown).
However, at these higher doses, imatinib produced ad-
verse effects, i.e., peritoneal adhesion and generalized
weakness. In contrast, imatinib at 25 mg/kg had no evident
adverse effect after 4 weeks. Biopsies of the liver, muscle,
kidney, heart, spleen, and other major organs conducted
after 4 weeks of 25 mg/kg imatinib treatment showed no
detectable abnormalities (supplementary Fig. 1, available
in an online appendix at http://dx.doi.org/10.2337/db08-
0080). Moreover, laboratory proﬁle did not show any
abnormality in blood cell counts or chemistry in db/db
mice treated with 25 mg/kg imatinib for 4 weeks except
hematocrit that was signiﬁcantly decreased compared
with control db/db mice but still within normal limits
(supplementary Table 1, available in the online appendix).
In addition, administration of 25 mg/kg imatinib for 4
weeks did not affect blood glucose levels, body weights, or
food intake in control C57BL/6 mice (P  0.1 for all points)
(Fig. 1A–C), suggesting that imatinib at 25 mg/kg for 4
weeks has no signiﬁcant toxicity or anorexic effect on
mice. Based on these results, we used the daily 25 mg/kg
protocol throughout the remainder of our study. Treat-
ment with 25 mg/kg imatinib for 4 weeks induced a small
but signiﬁcant decrease in body weight (P 	 0.05
0.005 at
2–4 weeks) (Fig. 1B) and food intake (P 	 0.01) (Fig. 1C)
of db/db mice. However, blood glucose levels in pair-fed
db/db mice were not signiﬁcantly different from those in
control db/db mice fed ad libitum (P  0.1 at all points)
(Fig. 1D), suggesting that reduction in blood glucose level
by imatinib cannot be explained by changes in food intake.
Body weight of pair-fed db/db mice was slightly but
signiﬁcantly decreased compared with control db/db mice
fed ad libitum (P 	 0.05 at 4 week) but not signiﬁcantly
different from that of db/db mice treated with imatinib
(P  0.1 at all points) (Fig. 1B), indicating that pair feeding
was done properly and reduction in blood glucose level by
imatinib cannot be explained by changes in food intake or
body weight.
Reduction of insulin resistance by imatinib. To assess
glucose homeostasis and insulin sensitivity in db/db mice
treated with imatinib, we conducted IPGTT after 25 mg/kg
imatinib administration for 4 weeks. Blood glucose levels
in control diabetic db/db mice after intraperitoneal injec-
tion of 1 g/kg glucose were signiﬁcantly higher than those
in control C57BL/6 mice, as expected (P 	 0.001 for all
points). In contrast, blood glucose levels after glucose
challenge to db/db mice treated with 25 mg/kg imatinib for
4 weeks were signiﬁcantly lower than those in control
db/db mice (P 	 0.001 for all points) and were similar to
those of control C57BL/6 mice (P  0.1 for all points) (Fig.
2A). To examine the effect of imatinib on insulin sensitiv-
ity, ITT was performed after 4 weeks of 25 mg/kg imatinib
administration. Intraperitoneal injection of 1 unit/kg regu-
lar insulin to diabetic db/db mice did not decrease blood
glucose level below untreated level, suggesting insulin
resistance in those mice. In contrast, blood glucose levels
in db/db mice treated with 25 mg/kg imatinib for 4 weeks
were signiﬁcantly lower than those in control db/db mice
since 30 min after insulin injection (P 	 0.05–0.005) and
were not different from those in C57BL/6 mice (P  0.1 for
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glucose levels in db/db mice by enhancing insulin sensitiv-
ity (Fig. 2B). Probably because of the decrease of insulin
resistance, fasting serum insulin level (0 min) in control
db/db mice that was markedly higher than that in C57BL/6
mice (P 	 0.001) was signiﬁcantly reduced by imatinib
treatment for 4 weeks as determined by Wilcoxon’s rank-
sum test (P 	 0.05) (Fig. 2C). To examine the changes of
-cell function by imatinib treatment, in vivo insulin
response to intraperitoneal injection of 1 g/kg glucose was
measured. Insulinogenic index calculated from serum in-
sulin level before (0 min) and 15 min after glucose
challenge was not signiﬁcantly different between imatinib-
treated and control db/db mice (P  0.1) (Fig. 2C),
suggesting that reduction of insulin resistance but not the
improved insulin secretion explains most of the remission
of diabetes in db/db mice by imatinib treatment.
Reduction of endoplasmic reticulum stress responses
by imatinib in vivo. We next studied the mechanism
underlying the improved insulin sensitivity in imatinib-
treated db/db mice. We ﬁrst studied the effect of imatinib
on endoplasmic reticulum stress because endoplasmic
reticulum stress has been reported to play a causative role
in insulin resistance (6) and because Abl kinase, which is
a target of imatinib, has been reported to play a role in the
initiation of endoplasmic reticulum stress and the media-
tion of endoplasmic reticulum stress responses (21,22).
When endoplasmic reticulum stress markers were exam-
ined in the liver and adipose tissues of fasted control db/db
mice, the expression of phospho-PERK, phospho-eIF2,
TRB3, and CHOP was found to be markedly increased as
previously reported (6). Intriguingly, upregulated expres-
sion of endoplasmic reticulum stress molecules was re-
markably reduced both in the liver and adipose tissues by
imatinib at 25 mg/kg for 4 weeks, suggesting that imatinib
leads to the improvement of diabetes in db/db mice by
attenuating endoplasmic reticulum stress (Fig. 3A).
Next, we examined JNK activation because JNK activa-
tion is an important component of endoplasmic reticulum
stress responses (23) and is critically involved in obesity-
induced insulin resistance (7,24). JNK was activated in the
liver and adipose tissues of control db/db mice, and this
was markedly reduced by imatinib treatment for 4 weeks
(Fig. 3B), consistent with the reductions in the expression
of other endoplasmic reticulum stress molecules, such as
phospho-PERK and CHOP, and also with previous papers
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FIG. 1. Effect of imatinib on diabetes of db/db mice. A: Imatinib (25 mg  kg
1  day
1) was administered intraperitoneally to 
5- to 7-week-old
diabetic db/db mice and control C57BL/6 mice for 4 weeks, and nonfasting blood glucose levels were determined. B: Body weight was monitored
during treatment of db/db or C57BL/6 mice with 25 mg/kg imatinib or PBS. That of pair-fed db/db mice was also shown. C: Food intake of db/db
and C57BL/6 mice treated with 25 mg/kg imatinib for 4 weeks. Food intake during the last week of the treatment was compared. D: Nonfasting
blood glucose levels were determined in control db/db mice and pair-fed db/db mice. *P < 0.05; **P < 0.01; ***P < 0.005 vs. control db/db mice
treated with PBS. E, db/db-PBS (A and B, n  13; D, n  7); F, db/db-Imatinib (A and B, n  13); , B6-PBS (A and B, n  8); f, B6-Imatinib (A
and B, n  8); ‚, db/db-Pair-fed (B and D, n  6).
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tion (25,26). We next investigated whether insulin signal-
ing is improved by imatinib because of amelioration of
endoplasmic reticulum stress. We studied the serine phos-
phorylation of IRS-1 because Ser307 phosphorylation of
IRS-1 by activated JNK plays an important role in insulin
resistance by inhibiting subsequent insulin signaling
through IRS-1 (27). IRS-1 Ser307 phosphorylation was
increased in the liver and adipose tissues of db/db mice
compared with C57BL/6 mice, as expected, and imatinib
treatment for 4 weeks attenuated the increased IRS-1
Ser307 phosphorylation (Fig. 3B). When we examined
insulin signaling after 5 units/kg insulin injection in vivo,
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FIG. 2. Effect of imatinib on insulin resistance of db/db mice. A: IPGTT
was conducted by injecting 1 g/kg glucose intraperitoneally into db/db
mice or control C57BL/6 mice treated with 25 mg/kg imatinib or PBS for
4 weeks and measuring blood glucose levels at the indicated time
points. B: ITT was done by injecting 1 unit/kg regular insulin intraperi-
toneally into db/db mice or control C57BL/6 mice treated with 25 mg/kg
imatinib or PBS for 4 weeks and measuring blood glucose levels at the
indicated time points. C: Serum was obtained from db/db mice or
control C57BL/6 mice treated with 25 mg/kg imatinib or PBS before (0
min) and 15 min after intraperitoneal injection of 1 g/kg glucose, and
insulin levels were measured by enzyme-linked immunosorbent assay.
Insulinogenic index was calculated using insulin levels at 0 and 15 min.
*P < 0.05; ***P < 0.005 vs. control db/db mice treated with PBS (15);
###P < 0.005 vs. control C57BL/6 mice treated with PBS. E, db/db-PBS
(A, n  10; B, n  8); F, db/db-Imatinib (A, n  10; B, n  8); , B6-PBS
(A and B, n  8); f, B6-Imatinib (A and B, n  8).
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FIG. 3. Attenuation of endoplasmic reticulum stress in the insulin
target tissues by imatinib treatment. A: Expression of endoplasmic
reticulum stress markers, such as phospho-PERK, phospho-eIF2,
TRB, and CHOP, were determined by Western blotting of the liver and
adipose tissues from fasted db/db and C57BL/6 mice treated with 25
mg/kg imatinib or PBS for 4 weeks. B: Insulin resistance markers in the
liver and adipose tissues of db/db and C57BL/6 mice were studied by
Western blotting using antibody to phospho-JNK or phospho-IRS-1
Ser307. C: In vivo insulin signaling was examined by investigating
phosphorylation of IRS-1 Tyr612 and Akt Thr308 using Western blot-
ting of the liver and adipose tissues from imatinib-treated db/db mice,
PBS-treated db/db mice, and C57BL/6 mice 5 min after insulin injection
into the tail vein.
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Thr308 downstream of IRS-1 (29) were reduced in the liver
and adipose tissues of db/db mice compared with C57BL/6
mice, as expected (Fig. 3C). Here, imatinib treatment for 4
weeks restored the reduced IRS-1 Tyr612 and Akt Thr308
phosphorylation in response to insulin (Fig. 3C), suggest-
ing that imatinib improved insulin signaling through IRS-1
and Akt by decreasing JNK activation and IRS-1 Ser307
phosphorylation.
We next studied changes of the lipid metabolism in the
liver because obesity-induced insulin resistance is associ-
ated with fatty liver disease both in human and mice.
Microscopic examination revealed a remarkable reduction
in degree of steatosis in db/db mice treated with imatinib
at 25 mg/kg for 4 weeks (Fig. 4A). Consistent with this
improvement of steatosis, serum ALT/AST levels and
hepatic TG contents were signiﬁcantly lower in imatinib-
treated db/db mice compared with control db/db mice as
determined by Wilcoxon’s rank-sum test (P 	 0.05) (Fig.
4B and C). The same test also showed that serum TG was
signiﬁcantly lower in imatinib-treated db/db mice com-
pared with control db/db mice (P 	 0.05) (Fig. 4D).
We next studied pancreatic -cell changes because
pancreatic -cells have adaptive capacity to changing
insulin resistance and -cell failure is the ultimate cause of
diabetes (30,31). Relative -cell area in db/db mice was
signiﬁcantly increased by imatinib treatment for 4 weeks
(P 	 0.05) (Fig. 5A). To study the mechanism underlying
this effect, we conducted TUNEL staining combined with
insulin immunohistochemistry. Numbers of TUNEL
 apo-
ptotic -cells per unit islet area were signiﬁcantly de-
creased by imatinib treatment (P 	 0.05) (Fig. 5B). We also
counted the numbers of BrdU-stained -cells as a measure
of -cell proliferation. Numbers of BrdU
-proliferating
-cells per unit islet area were signiﬁcantly increased by
imatinib treatment (P 	 0.05) (Fig. 5C), suggesting that
imatinib protects -cell mass by reducing -cell death and
increasing -cell proliferation after reduction of insulin
resistance.
Reduction of endoplasmic reticulum stress responses
by imatinib in vitro. Next, we studied whether the
observed amelioration of endoplasmic reticulum stress in
vivo by imatinib is due to the direct cell-autonomous effect
of imatinib on endoplasmic reticulum stress or an indirect
result of a complex in vivo interaction among diverse
pathways. When endoplasmic reticulum stress was in-
duced in HepG2 hepatoma cells by 250–1,000 nmol/l
thapsigargin or 0.1–1 g/ml tunicamycin (32), expression
of phospho-PERK, phospho-eIF2, and phospho-JNK was
increased, as expected. Here, combined treatment with 10
mol/l imatinib markedly downregulated the expression
of all three of these endoplasmic reticulum stress mole-
cules in HepG2 cells, suggesting that imatinib directly
ameliorates cellular endoplasmic reticulum stress (Fig. 6A
and B). In contrast, the same imatinib treatment did not
affect JNK activation by anisomycin that is known to
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FIG. 4. Amelioration of steatosis of db/db mice by imatinib. A: Liver sections were prepared from db/db or control C57BL/6 mice treated with 25
mg/kg imatinib or PBS for 4 weeks, and hematoxylin-eosin staining was done. B: Serum was obtained from fasted db/db or C57BL/6 mice treated
with 25 mg/kg imatinib or PBS for 4 weeks, and ALT/AST levels were measured using a chemical analyzer. C: Lipid was extracted from the liver
of db/db or C57BL/6 mice treated with 25 mg/kg imatinib or PBS for 4 weeks using chloroform/ethanol mixture, and tissue TG levels were
measured using Free Glycerol Reagent containing lipase. D: Serum was obtained from fasted db/db or C57BL/6 mice treated with 25 mg/kg
imatinib or PBS for 4 weeks, and serum TG levels were measured using a blood chemistry analyzer. *P < 0.05 vs. control db/db mice treated
with PBS.
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(6), thus demonstrating the speciﬁcity of the effect of
imatinib on endoplasmic reticulum stress–related JNK
activation (Fig. 6C).
DISCUSSION
Observations made in patients with CML and concomitant
type 2 diabetes suggest that imatinib might have a beneﬁ-
cial effect on diabetes (10,11). However, the observed
reductions in blood glucose levels in patients with CML
and type 2 diabetes might have been caused by nonspeciﬁc
effects attributable to improved general health status
achieved by treating CML with imatinib, and thus, those
reports do not allow an assessment of the effect of
imatinib on diabetes itself. Furthermore, one study con-
cluded that imatinib has no effect on human type 2
diabetes (33). While this work was in preparation, a study
showing the effect of imatinib on diet-induced obesity and
insulin resistance was published (34). However, the mech-
anism of the amelioration of the insulin resistance by
imatinib was not investigated, and the effect of imatinib on
diabetic db/db mice with elevated blood glucose levels was
not tested. In fact, imatinib administration increased blood
glucose levels in rats on high-fat diet (34). The present
study clearly demonstrates that imatinib dramatically re-
duces elevated blood glucose levels and has therapeutic
effects on type 2 diabetes, at least in this animal model.
In addition to the remission of diabetes, imatinib admin-
istration induced a small but signiﬁcant decrease of body
weight and food intake in db/db mice. Such effects might
be due to the improved anorexigenic effect of insulin
caused by increased insulin sensitivity after imatinib ad-
ministration (35). Possible direct effect of imatinib on the
hypothalamus or systemic toxic effect of imatinib cannot
be eliminated as potential causes of the decreased body
weight. However, we consider that the possibility of
systemic toxicity is quite low because the dose of imatinib
used in this investigation was much lower than that used
in animal models of cancer (8,20). Moreover, imatinib
administration did not affect the body weight or food
intake of C57BL/6 mice. Histological analysis of the major
organs and blood cell/chemistry proﬁles produced no
evidence of systemic toxicity, further supporting the ab-
sence of signiﬁcant systemic toxicity.
Imatinib has been reported to affect glucose metabo-
lism, e.g., it reduces glucose utilization by cancer cells
(36,37). In fact, this has been considered to be a mecha-
nism of tumor regression by imatinib (37). However,
reduced glucose utilization cannot explain the improved
glucose control in patients or animals with type 2 diabetes.
In the present study, we explored the possibility that
endoplasmic reticulum stress modulation by imatinib in-
duces the remission of diabetes because c-Abl or Bcr-Abl
kinase has been reported to participate in cellular re-
sponse to endoplasmic reticulum stress (21) or in the
initiation of endoplasmic reticulum stress by reducing
endoplasmic reticulum Ca
2 content (22). Consistent with
our hypothesis, expression of endoplasmic reticulum
stress molecules in insulin target tissues of db/db mice was
markedly reduced by imatinib treatment. These effects of
c-Abl kinase and its inhibitor imatinib on endoplasmic
reticulum stress responses are consistent with the abro-
gation of endoplasmic reticulum stress–induced cell death
or JNK activation in c-Abl–null cells (21,25) and appear to
be related to the localization of c-Abl kinase in endoplas-
mic reticulum and mitochondria as well as cytoplasm and
nucleus (21,22). Because endoplasmic reticulum stress has
been reported to play an important role in obesity-induced
insulin resistance (6) and because chemical chaperones
relieving endoplasmic reticulum stress have been shown
to reverse diabetes (38), our ﬁndings provide a rational
explanation for the effect of imatinib on diabetes in db/db
mice. A recent article suggested that activation of endo-
plasmic reticulum stress after imatinib is a cause of
imatinib-induced cardiomyopathy (39). However, the dose
of imatinib used in that study (50–200 mg  kg
1  day
1 for
3–6 weeks) was much higher than that used in this
investigation, and the response to imatinib may be dose
and tissue dependent.
Increase of -cell mass by imatinib treatment could be
also attributable to the reduction of endoplasmic reticu-
lum stress in -cells that has been observed in obese
subjects or animals with type 2 diabetes (30,31), although
we did not explore this possibility further and the ultimate
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FIG. 5. Changes in -cell mass by imatinib treatment. A: After immunostaining of pancreatic sections from imatinib-treated or control db/db mice
using anti-insulin antibody as the primary antibody, point-counting morphometry was conducted to measure the relative -cell area. B: After
TUNEL staining of pancreatic sections from imatinib-treated or control db/db mice, immunohistochemistry using anti-insulin antibody was
performed. Numbers of TUNEL
 apoptotic -cells stained with anti-insulin antibody were counted and normalized to islet area measured by a
computer-assisted method. C: Immunostaining using anti-BrdU antibody was conducted on pancreatic sections from of imatinib-treated or control
db/db mice to which 100 g/g BrdU was injected intraperitoneally. After subsequent immunohistochemistry using anti-insulin antibody, numbers
of BrdU
 -cells were calculated and normalized as in B.* P < 0.05 vs. control db/db mice treated with PBS.
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trol and improved -cell mass remains to be clariﬁed.
The molecular and cellular mechanisms of endoplasmic
reticulum stress attenuation by imatinib are unknown.
Changes in endoplasmic reticulum Ca
2 content by c-Abl
or imatinib (22) may be involved in this modulation of
endoplasmic reticulum stress by imatinib. We observed
the cell-intrinsic effects of imatinib on endoplasmic retic-
ulum stress induced by thapsigargin and tunicamycin that
are typical endoplasmic reticulum stressor agents inhibit-
ing endoplasmic reticulum Ca
2-ATPase and posttransla-
tional protein glycosylation at endoplasmic reticulum,
respectively (40). However, other indirect effects of ima-
tinib on endoplasmic reticulum stress may also play a role
in the reduction of endoplasmic reticulum stress in vivo.
For instance, imatinib has been reported to inhibit TNF-
production in the liver (41) that may be related to endo-
plasmic reticulum stress observed in obesity-induced in-
sulin resistance (42).
The decreased JNK activation by imatinib observed in
the liver of db/db mice is consistent with amelioration of
endoplasmic reticulum stress, reduced IRS-1 Ser307 phos-
phorylation, and an increase in insulin-induced phosphor-
ylation of IRS-1 Tyr612 or Akt Thr308, because JNK
activation is an important part in endoplasmic reticulum
stress response (23) and because JNK activation has been
reported to induce insulin resistance by phosphorylating
IRS-1 at Ser307 (27). These results are also consistent with
previous reports showing reduced JNK activation in leu-
kemic cells by imatinib (26) or those reporting a critical
role for c-Abl kinase in JNK activation by anticancer
agents or growth factors (25,43). However, these ﬁndings
are at odds with those of another study reporting de-
creased constitutive IRS-1 signaling after imatinib treat-
ment of leukemic cells (44). The effect of imatinib on
constitutive IRS-1 signaling in cancer cells might differ
from that on insulin-induced IRS-1 signaling in insulin
target tissues.
The above ﬁndings suggest the possibility that the target
of imatinib involved in the improvement of diabetes in
db/db mice is c-Abl kinase itself. This speculation is
supported by a previous observation that downregulation
of c-Abl mRNA by siRNA protected insulinoma cells from
cytokine-induced death (13). Imatinib was originally de-
veloped as a speciﬁc inhibitor of Abl kinase, however,
other targets have been identiﬁed, such as Kit and platelet-
derived growth factor receptor kinases (9,45). Hence, the
existence of other molecular species that mediate the
antidiabetic effect of imatinib cannot be eliminated. Be-
cause imatinib was initially developed for life-threatening
diseases and has common side effects that may prevent its
development as an antidiabetic agent, it is unclear whether
imatinib or its related compounds could be used as
therapeutic agents against diabetes. However, if more
speciﬁc inhibitors of Abl kinase could be developed or
new molecular targets of imatinib mediating its antidia-
betic effects could be identiﬁed, they would provide excel-
lent bases for the development of new antidiabetic agents.
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